Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: Preliminary results

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 105-112

  Buckley, Susan E ^a   Saran, Frank H ^a   Gaze, Mark N ^b   Chittenden, Sarah ^a   Partridge, Mike ^a,c   Lancaster, Donna ^a   Pearson, Andrew ^c   Flux, Glenn D ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

131I mIBG; Dosimetry; Neuroblastoma; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; TOPOTECAN;

CALIBRATION; CANCER RESISTANCE; CASE REPORT; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSIMETRY; FEMALE; HALF LIFE TIME; HIGH RISK PATIENT; HUMAN; MALE; NEUROBLASTOMA; PHANTOM; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY RADIATION;

3-IODOBENZYLGUANIDINE; CHILD, PRESCHOOL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; RADIOMETRY; TIME FACTORS;

EID: 34247869771     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.301     Document Type: Conference Paper

References (16)

1. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264.
2. 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003;25:769.
3. Matthay KK, Villablanca JD, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165.
4. 131I-mIBG. J Nucl Med 2001;42:1713.
5. Hoefnagel CA, Voute PA, de Kraker J, et al. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308.
6. 131I]meta- iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929.
7. Gaze MN, Chang Y, Flux GD, et al. Feasibility of dosimetry-based high-dose 131-metaiodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195.
8. Flux GD, Guy MJ, Papavasileiou P, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18:81.
9. Loevinger RL, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York: Society of Nuclear Medicine, 1988.
10. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources. In: ORNL/TM-8381 V1-V7. Oak Ridge, TN: Oak Ridge National laboratory, 1987.
11. Bolster A. Report 86: Quality Control of Gamma Camera Systems. New York: Institute of Physics and Engineering in Medicine, 2003.
12. Flux GD, Guy MJ, Beddows R, et al. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47:3211.
13. Medical Internal Radiation Dose committee. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimation (MIRD Pamphlet 10), New York: Society of Nuclear Medicine, 1975.
14. Stabin MG, Konijnenberg MW. Reevaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41:149.
15. 131I-MIBG therapy for neuroendocrine tumors based on 123-MIBG scans. Eur J Nucl Med 2002;29:1581.
16. Liu A, Williams LE, Demidecki AJ, et al. Modelling of tumor uptake to determine time-dose-fractionation effect in radioimmunotherapy. J Nucl Med 1994;35:1561.